Expertise and rankings

  • Experience. Mayo Clinic is a leader in the treatment of polycystic kidney disease. Each year, doctors at the three Mayo Clinic locations care for about a 1,000 patients who have polycystic kidney disease.
  • Pediatric expertise. Mayo Clinic in Rochester, Minnesota, offers diagnosis, care and treatment in a child-friendly environment for children who have autosomal recessive polycystic kidney disease or complications of autosomal dominant polycystic kidney disease.

    In Mayo's efficient system, your child can see multiple specialists and receive testing and treatment in days, not months. The care team also includes nurse specialists, social workers, dietitians and behavioral health specialists.

  • Renowned transplant program. A number of referrals to our kidney transplant program have polycystic kidney disease. If you require a kidney transplant, you'll receive a timely referral to transplant specialists at Mayo Clinic's kidney transplant program.

Learn more about Mayo Clinic's nephrology and hypertension department's expertise and rankings.

Mayo Clinic in Rochester, Minn., ranks No. 1 for kidney disorders in the U.S. News & World Report Best Hospitals rankings. Mayo Clinic in Scottsdale, Ariz., ranks among the Best Hospitals for kidney disorders by U.S. News & World Report. Mayo Clinic in Jacksonville, Fla., is ranked high performing for kidney disorders by U.S. News & World Report.

July 13, 2017
References
  1. Polycystic kidney disease. National Kidney and Urologic Diseases Information Clearinghouse. http://kidney.niddk.nih.gov/kudiseases/pubs/polycystic/. Accessed March 11, 2017.
  2. Chapman AB, et al. Course and treatment of autosomal dominant polycystic kidney disease. https://www.uptodate.com/home. Accessed March 11, 2017.
  3. Polycystic kidney disease. American Kidney Fund. http://www.kidneyfund.org/kidney-disease/other-kidney-conditions/polycystic-kidney-disease.html?&gclid=Cj0KEQiA3Y7GBRD29f-7kYuO1-ABEiQAodAvwGAsS7ELsM8hNXkbCPt3pE8hsRp-kijSf4UAs-ZmPVgaArPQ8P8HAQ. Accessed March 11, 2017.
  4. Bennett WM, et al. Extrarenal manifestations of autosomal dominant polycystic kidney disease. https://www.uptodate.com/home. Accessed March 11, 2017.
  5. Polycystic kidney disease. National Kidney Foundation. https://www.kidney.org/atoz/content/polycystic. Accessed March 11, 2017.
  6. Torres VE, et al. Diagnosis and screening for autosomal dominant polycystic kidney disease. https://www.uptodate.com/home. Accessed March 11, 2017.
  7. Albert CM, et al. Autosomal dominant polycystic kidney disease: The changing face of clinical management. The Lancet. 2015;385:1993.
  8. Rossetti S, et al. Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. Journal of the American Society of Nephrology. 2012;23:915.
  9. Torres VE, et al. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. Journal of the American Society of Nephrology. 2014; 25:18.
  10. Shoaf SE, et al. Pharmacokinetics and pharmacodynamics of Tolvaptan in autosomal dominat polycystic kidney disease: Phase 2 trials for dose selection in the pivotal phase 3 trial. The Journal of Clinical Pharmacology. In press. Accessed March 11, 2017.
  11. Hogan MC, et al. Somatostatin analog therapy for severe polycystic liver disease: Results after 2 years. Nephrology Dialysis Transplantation. 2012;27:3532.
  12. Riggin EA. Allscripts EPSi. Mayo Clinic, Rochester, Minn. Jan. 24, 2017.